Patents by Inventor Niclas Axel Petri

Niclas Axel Petri has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • ADMINISTRATION OF A SELECTIVE IL-6-TRANS-SIGNALLING INHIBITOR
    Publication number: 20220135652
    Abstract: A selective IL-6-trans-signalling inhibitor can be used to treat a variety of IL-6-mediated conditions, including inflammatory diseases and cancer. The inhibitor can safely be administered to humans at a variety of doses. Moreover, the inhibitor lessens deleterious effects associated with other IL-6 inhibitors such as lowering neutrophil counts, platelet counts and levels of C-reactive protein.
    Type: Application
    Filed: November 9, 2021
    Publication date: May 5, 2022
    Inventors: Ian Cottingham, Niclas Axel Petri
  • Methods for treatment of inflammatory disease or IL-6-mediated condition with gp130 protein
    Patent number: 11198721
    Abstract: A selective IL-6-trans-signalling inhibitor can be used to treat a variety of IL-6-mediated conditions, including inflammatory diseases and cancer. The inhibitor can safely be administered to humans at a variety of doses. Moreover, the inhibitor lessens deleterious effects associated with other IL-6 inhibitors such as lowering neutrophil counts, platelet counts and levels of C-reactive protein.
    Type: Grant
    Filed: December 1, 2015
    Date of Patent: December 14, 2021
    Assignee: Ferring B.V.
    Inventors: Ian Cottingham, Niclas Axel Petri
  • ADMINISTRATION OF A SELECTIVE IL-6-TRANS-SIGNALLING INHIBITOR
    Publication number: 20170320932
    Abstract: A selective IL-6-trans-signalling inhibitor can be used to treat a variety of IL-6-mediated conditions, including inflammatory diseases and cancer. The inhibitor can safely be administered to humans at a variety of doses. Moreover, the inhibitor lessens deleterious effects associated with other IL-6 inhibitors such as lowering neutrophil counts, platelet counts and levels of C-reactive protein.
    Type: Application
    Filed: December 1, 2015
    Publication date: November 9, 2017
    Inventors: Ian Cottingham, Niclas Axel Petri